相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non-Small Cell Lung Cancer
Hossein Borghaei et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001
O. Hamid et al.
ANNALS OF ONCOLOGY (2019)
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC (vol 28, pg 1339, 2017)
J. J. Knox et al.
ANNALS OF ONCOLOGY (2018)
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
M. A. Socinski et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer
L. Gandhi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
M. D. Hellmann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Cancer-associated fibroblasts induce antigen-specific deletion of CD8+ T Cells to protect tumour cells
Matthew A. Lakins et al.
NATURE COMMUNICATIONS (2018)
Serum interleukin 8 (IL-8) may serve as a biomarker of response to immuno-oncology (I-O) therapy.
Michael Carleton et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer
L. Paz-Ares et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Hypoxic stress: obstacles and opportunities for innovative immunotherapy of cancer
S. Chouaib et al.
ONCOGENE (2017)
Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations
Daniel Sanghoon Shin et al.
CANCER DISCOVERY (2017)
Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors
Frederick Arce Vargas et al.
IMMUNITY (2017)
TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy
William C. Dougall et al.
IMMUNOLOGICAL REVIEWS (2017)
PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project
Fred R. Hirsch et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Elements of cancer immunity and the cancer-immune set point
Daniel S. Chen et al.
NATURE (2017)
Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming
Lin Tian et al.
NATURE (2017)
T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition
Enfu Hui et al.
SCIENCE (2017)
Rescue of exhausted CD8 T cells by PD-1-targeted therapies is CD28-dependent
Alice O. Kamphorst et al.
SCIENCE (2017)
Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade
Martina Schmittnaegel et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation
Elizabeth Allen et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Resistance to checkpoint blockade therapy through inactivation of antigen presentation
Moshe Sade-Feldman et al.
NATURE COMMUNICATIONS (2017)
Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
Jie Bai et al.
ONCOTARGET (2017)
Resistance to PD1/PDL1 checkpoint inhibition
Jake S. O'Donnell et al.
CANCER TREATMENT REVIEWS (2017)
Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients
M. F. Sanmamed et al.
ANNALS OF ONCOLOGY (2017)
Agreement between Programmed Cell Death Ligand-1 Diagnostic Assays across Multiple Protein Expression Cutoffs in Non-Small Cell Lung Cancer
Marianne J. Ratcliffe et al.
CLINICAL CANCER RESEARCH (2017)
Initial efficacy of anti-lymphocyte activation gene-3 (anti-LAG-3; BMS-986016) in combination with nivolumab (nivo) in pts with melanoma (MEL) previously treated with anti-PD-1/PD-L1 therapy.
Paolo Antonio Ascierto et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Padmanee Sharma et al.
CELL (2017)
Tumor-associated macrophages in cancers
W. Hu et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2016)
CD73 Expression Is an Independent Prognostic Factor in Prostate Cancer
Bruno G. Leclerc et al.
CLINICAL CANCER RESEARCH (2016)
Heterogeneity of Programmed Cell Death Ligand 1 Expression in Multifocal Lung Cancer
Aaron S. Mansfield et al.
CLINICAL CANCER RESEARCH (2016)
Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy
Weiyi Peng et al.
CANCER DISCOVERY (2016)
Combined treatment with dabrafenib and trametinib with immune-stimulating antibodies for BRAF mutant melanoma
Blanca Homet Moreno et al.
ONCOIMMUNOLOGY (2016)
Adenosine 2B Receptor Expression on Cancer Cells Promotes Metastasis
Deepak Mittal et al.
CANCER RESEARCH (2016)
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
Willy Hugo et al.
CELL (2016)
Systematic review of case reports on the abscopal effect
Yazan Abuodeh et al.
CURRENT PROBLEMS IN CANCER (2016)
Rationale for anti-OX40 cancer immunotherapy
Sandrine Aspeslagh et al.
EUROPEAN JOURNAL OF CANCER (2016)
The TNF Receptor Superfamily in Co-stimulating and Co-inhibitory Responses
Lindsay K. Ward-Kavanagh et al.
IMMUNITY (2016)
Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors
Jonathan M. Pitt et al.
IMMUNITY (2016)
Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma
Antoni Ribas et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma
Igor Puzanov et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial
Padmanee Sharma et al.
LANCET ONCOLOGY (2016)
Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells
Olivier De Henau et al.
NATURE (2016)
PI3Kγ is a molecular switch that controls immune suppression
Megan M. Kaneda et al.
NATURE (2016)
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
R. L. Ferris et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
The cancer immunogram
Christian U. Blank et al.
SCIENCE (2016)
Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
Shohei Koyama et al.
NATURE COMMUNICATIONS (2016)
A Phase I study of indoximod in patients with advanced malignancies
Hatem H. Soliman et al.
ONCOTARGET (2016)
Efficacy analysis of MASTERKEY-265 phase lb study of talimogene laherparepvec (T-VEC) and pembrolizumab (pembro) for unresectable stage IIIB-IV melanoma.
Georgina V. Long et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Macrophages and Therapeutic Resistance in Cancer
Brian Ruffell et al.
CANCER CELL (2015)
TGFβ Is a Master Regulator of Radiation Therapy-Induced Antitumor Immunity
Claire Vanpouille-Box et al.
CANCER RESEARCH (2015)
CD73 Is Associated with Poor Prognosis in High-Grade Serous Ovarian Cancer
Martin Turcotte et al.
CANCER RESEARCH (2015)
Updated results from a phase 1/2 study of epacadostat (INCB024360) in combination with ipilimumab in patients with metastatic melanoma
G. Gibney et al.
EUROPEAN JOURNAL OF CANCER (2015)
Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial
Robert J. Motzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
Robert H. I. Andtbacka et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
Dirk Schadendorf et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
Stefani Spranger et al.
NATURE (2015)
Combination cancer immunotherapy and new immunomodulatory targets
Kathleen M. Mahoney et al.
NATURE REVIEWS DRUG DISCOVERY (2015)
Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
Michael A. Postow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Severe gastrointestinal toxicity with administration of trametinib in combination with dabrafenib and ipilimumab
David R. Minor et al.
PIGMENT CELL & MELANOMA RESEARCH (2015)
Adaptive Immune Resistance: How Cancer Protects from Immune Attack
Antoni Ribas
CANCER DISCOVERY (2015)
Macrophage depletion reduces postsurgical tumor recurrence and metastatic growth in a spontaneous murine model of melanoma
Muly Tham et al.
ONCOTARGET (2015)
Tumor-Expressed IDO Recruits and Activates MDSCs in a Treg-Dependent Manner
Rikke B. Holmgaard et al.
CELL REPORTS (2015)
Induced PD-L1 Expression Mediates Acquired Resistance to Agonistic Anti-CD40 Treatment
Alfred Zippelius et al.
CANCER IMMUNOLOGY RESEARCH (2015)
BRAFV600E Co-opts a Conserved MHC Class I Internalization Pathway to Diminish Antigen Presentation and CD8+ T-cell Recognition of Melanoma
Sherille D. Bradley et al.
CANCER IMMUNOLOGY RESEARCH (2015)
HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 Blockade
David M. Woods et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Modulation of APC function and anti-tumor immunity by anti-cancer drugs
Kea Martin et al.
FRONTIERS IN IMMUNOLOGY (2015)
CD73: A potential biomarker for anti-PD-1 therapy
Paul A Beavis et al.
OncoImmunology (2015)
Role of Local Radiation Therapy in Cancer Immunotherapy
Sandra Demaria et al.
JAMA ONCOLOGY (2015)
Safety, Correlative Markers, and Clinical Results of Adjuvant Nivolumab in Combination with Vaccine in Resected High-Risk Metastatic Melanoma
Geoffrey T. Gibney et al.
CLINICAL CANCER RESEARCH (2015)
OX40-and CD27-Mediated Costimulation Synergizes with Anti-PD-L1 Blockade by Forcing Exhausted CD8+ T Cells To Exit Quiescence
Sarah L. Buchan et al.
JOURNAL OF IMMUNOLOGY (2015)
Combination of 4-1BB Agonist and PD-1 Antagonist Promotes Antitumor Effector/Memory CD8 T Cells in a Poorly Immunogenic Tumor Model
Shihao Chen et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Molecular and cellular insights into T cell exhaustion
E. John Wherry et al.
NATURE REVIEWS IMMUNOLOGY (2015)
Immune Modulation in Cancer with Antibodies
David B. Page et al.
ANNUAL REVIEW OF MEDICINE, VOL 65 (2014)
The Immunoreceptor TIGIT Regulates Antitumor and Antiviral CD8+ T Cell Effector Function
Robert J. Johnston et al.
CANCER CELL (2014)
Targeting Tumor-Associated Macrophages with Anti-CSF-1R Antibody Reveals a Strategy for Cancer Therapy
Carola H. Ries et al.
CANCER CELL (2014)
Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab
Christiane Meyer et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2014)
Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer
George C. Prendergast et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2014)
Inhibition of CSF-1 Receptor Improves the Antitumor Efficacy of Adoptive Cell Transfer Immunotherapy
Stephen Mok et al.
CANCER RESEARCH (2014)
TLR7 Promotes Tumor Progression, Chemotherapy Resistance, and Poor Clinical Outcomes in Non-Small Cell Lung Cancer
Saradiya Chatterjee et al.
CANCER RESEARCH (2014)
Antimetastatic Effects of Blocking PD-1 and the Adenosine A2A Receptor
Deepak Mittal et al.
CANCER RESEARCH (2014)
Molecular Pathways: Myeloid Complicity in Cancer
Ingunn M. Stromnes et al.
CLINICAL CANCER RESEARCH (2014)
Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy
Janis M. Taube et al.
CLINICAL CANCER RESEARCH (2014)
STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors
Liufu Deng et al.
IMMUNITY (2014)
Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice
Liufu Deng et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy
Xiaozhou Fan et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2014)
CXCL12/CXCR4 Blockade by Oncolytic Virotherapy Inhibits Ovarian Cancer Growth by Decreasing Immunosuppression and Targeting Cancer-Initiating Cells
Margaret Gil et al.
JOURNAL OF IMMUNOLOGY (2014)
Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial
Eugene D. Kwon et al.
LANCET ONCOLOGY (2014)
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Roy S. Herbst et al.
NATURE (2014)
The Yin and Yang of Toll-like receptors in cancer
J-P Pradere et al.
ONCOGENE (2014)
Localized Oncolytic Virotherapy Overcomes Systemic Tumor Resistance to Immune Checkpoint Blockade Immunotherapy
Dmitriy Zamarin et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Disruption of CXCR2-Mediated MDSC Tumor Trafficking Enhances Anti-PD1 Efficacy
Steven L. Highfill et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Immune Cell-Poor Melanomas Benefit from PD-1 Blockade after Targeted Type I IFN Activation
Tobias Bald et al.
CANCER DISCOVERY (2014)
Targeting Cancer-Derived Adenosine: New Therapeutic Approaches
Arabella Young et al.
CANCER DISCOVERY (2014)
Killer Immunoglobulin-like Receptors and Tumor Immunity
Don M. Benson et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment
Stefani Spranger et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2014)
Tumor-Associated Macrophages as Major Players in the Tumor Microenvironment
Theerawut Chanmee et al.
CANCERS (2014)
Oncolytic immunotherapy: dying the right way is a key to eliciting potent antitumor immunity
Zong Sheng Guo et al.
FRONTIERS IN ONCOLOGY (2014)
Biomarker characterization using mass cytometry in a phase 1 trial of urelumab (BMS-663513) in subjects with advanced solid tumors and relapsed/refractory B-cell non-Hodgkin lymphoma.
Cariad Chester et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Phase I study of tremelimumab (CP-675 206) plus PF-3512676 (CPG 7909) in patients with melanoma or advanced solid tumours
M. Millward et al.
BRITISH JOURNAL OF CANCER (2013)
OX40 Is a Potent Immune-Stimulating Target in Late-Stage Cancer Patients
Brendan D. Curti et al.
CANCER RESEARCH (2013)
Dual Blockade of PD-1 and CTLA-4 Combined with Tumor Vaccine Effectively Restores T-Cell Rejection Function in Tumors
Jaikumar Duraiswamy et al.
CANCER RESEARCH (2013)
BRAF Inhibition Increases Tumor Infiltration by T cells and Enhances the Antitumor Activity of Adoptive Immunotherapy in Mice
Chengwen Liu et al.
CLINICAL CANCER RESEARCH (2013)
BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma
Dennie T. Frederick et al.
CLINICAL CANCER RESEARCH (2013)
Update on the role of ipilimumab in melanoma and first data on new combination therapies
Michele Maio et al.
CURRENT OPINION IN ONCOLOGY (2013)
Deciphering and Reversing Tumor Immune Suppression
Greg T. Motz et al.
IMMUNITY (2013)
Anti-PD-1 Blockade and Stereotactic Radiation Produce Long-Term Survival in Mice With Intracranial Gliomas
Jing Zeng et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2013)
Host immunity contributes to the anti-melanoma activity of BRAF inhibitors
Deborah A. Knight et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4
Rikke B. Holmgaard et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2013)
TLR agonists: our best frenemy in cancer immunotherapy
Sabina Kaczanowska et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2013)
Combined TIM-3 blockade and CD137 activation affords the long-term protection in a murine model of ovarian cancer
Zhiqiang Guo et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2013)
Co-Stimulation through 4-1BB/CD137 Improves the Expansion and Function of CD8+ Melanoma Tumor-Infiltrating Lymphocytes for Adoptive T-Cell Therapy
Jessica Ann Chacon et al.
PLOS ONE (2013)
CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer
Sherene Loi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans
Daisuke Sugiyama et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Molecular mechanisms of T cell co-stimulation and co-inhibition
Lieping Chen et al.
NATURE REVIEWS IMMUNOLOGY (2013)
The TIGIT/CD226 Axis Regulates Human T Cell Function
Ester Lozano et al.
JOURNAL OF IMMUNOLOGY (2012)
Humanization of an Anti-CCR4 Antibody That Kills Cutaneous T-Cell Lymphoma Cells and Abrogates Suppression by T-Regulatory Cells
De-Kuan Chang et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial
Ravi A. Madan et al.
LANCET ONCOLOGY (2012)
Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation
Jennifer Landsberg et al.
NATURE (2012)
Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma
Michael A. Postow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
TIM-3 Expression Characterizes Regulatory T Cells in Tumor Tissues and Is Associated with Lung Cancer Progression
Xin Gao et al.
PLOS ONE (2012)
A Systemic Complete Response of Metastatic Melanoma to Local Radiation and Immunotherapy
Susan M. Hiniker et al.
TRANSLATIONAL ONCOLOGY (2012)
Radiation as an immunological adjuvant: current evidence on dose and fractionation
Sandra Demaria et al.
FRONTIERS IN ONCOLOGY (2012)
CTLA4 Blockade Induces Frequent Tumor Infiltration by Activated Lymphocytes Regardless of Clinical Responses in Humans
Rong Rong Huang et al.
CLINICAL CANCER RESEARCH (2011)
CD70-CD27 interactions provide survival and proliferative signals that regulate T cell receptor-driven activation of human gamma delta peripheral blood lymphocytes
Ana deBarros et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2011)
A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naive patients with advanced melanoma
Evan M. Hersh et al.
INVESTIGATIONAL NEW DRUGS (2011)
Immune parameters affecting the efficacy of chemotherapeutic regimens
Laurence Zitvogel et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2011)
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Paul B. Chapman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
γ-Radiation Promotes Immunological Recognition of Cancer Cells through Increased Expression of Cancer-Testis Antigens In Vitro and In Vivo
Anu Sharma et al.
PLOS ONE (2011)
Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity
Xiangdong Liu et al.
BLOOD (2010)
Selective BRAFV600E Inhibition Enhances T-Cell Recognition of Melanoma without Affecting Lymphocyte Function
Andrea Boni et al.
CANCER RESEARCH (2010)
The Oncogenic BRAF Kinase Inhibitor PLX4032/RG7204 Does Not Affect the Viability or Function of Human Lymphocytes across a Wide Range of Concentrations
Begona Comin-Anduix et al.
CLINICAL CANCER RESEARCH (2010)
Hypoxia-inducible adenosine A2B receptor modulates proliferation of colon carcinoma cells
De-Fu Ma et al.
HUMAN PATHOLOGY (2010)
Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients
Julien Fourcade et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Agonist Anti-GITR Monoclonal Antibody Induces Melanoma Tumor Immunity in Mice by Altering Regulatory T Cell Stability and Intra-Tumor Accumulation
Adam D. Cohen et al.
PLOS ONE (2010)
PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors
Michael A. Curran et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer
Junko Matsuzaki et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Enhanced Antitumor Activity Induced by Adoptive T-Cell Transfer and Adjunctive Use of the Histone Deacetylase Inhibitor LAQ824
Dan D. Vo et al.
CANCER RESEARCH (2009)
Fractionated but Not Single-Dose Radiotherapy Induces an Immune-Mediated Abscopal Effect when Combined with Anti-CTLA-4 Antibody
M. Zahidunnabi Dewan et al.
CLINICAL CANCER RESEARCH (2009)
Anti-Programmed Death-1 Synergizes with Granulocyte Macrophage Colony-Stimulating Factor-Secreting Tumor Cell Immunotherapy Providing Therapeutic Benefit to Mice with Established Tumors
Betty Li et al.
CLINICAL CANCER RESEARCH (2009)
Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation
G. Solinas et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2009)
The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells
Xin Yu et al.
NATURE IMMUNOLOGY (2009)
The role of TNF superfamily members in T-cell function and diseases
Michael Croft
NATURE REVIEWS IMMUNOLOGY (2009)
Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis
Li Yang et al.
CANCER CELL (2008)
Regulatory T cells and immune tolerance
Shimon Sakaguchi et al.
CELL (2008)
Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways
Brian T. Fife et al.
IMMUNOLOGICAL REVIEWS (2008)
CTLA-4 control over Foxp3+ regulatory T cell function
Kajsa Wing et al.
SCIENCE (2008)
Phase 1, pharmacokinetic (PK) and pharmacodynamic (PD) study of oral alvespimycin (A; KOS-1022; 17-DMAG): Two different schedules in patients with advanced malignancies
K. T. Flaherty et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody
Robert H. Vonderheide et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Depletion of CD4+CD25+ regulatory T cells promotes a tumor-specific immune response in pancreas cancer-bearing mice
Carsten T. Viehl et al.
ANNALS OF SURGICAL ONCOLOGY (2006)
Functional characterization of OX40 expressed on human CD8+ T cells
Tomoko Fujita et al.
IMMUNOLOGY LETTERS (2006)
CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells
Sergio A. Quezada et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma
SA Rosenberg et al.
JOURNAL OF IMMUNOLOGY (2005)
Immunity to melanoma mediated by 4-1BB is associated with enhanced activity of tumour-infiltrating lymphocytes
SA Ju et al.
IMMUNOLOGY AND CELL BIOLOGY (2005)
A critical function for type I interferons in cancer immunoediting
GP Dunn et al.
NATURE IMMUNOLOGY (2005)
CD25(+)CD4(+) regulatory T-cells in cancer
DC Linehan et al.
IMMUNOLOGIC RESEARCH (2005)
Adenosine acts through A2 receptors to inhibit IL-2-induced tyrosine phosphorylation of STAT5 in T lymphocytes:: Role of cyclic adenosine 3',5'-monophosphate and phosphatases
H Zhang et al.
JOURNAL OF IMMUNOLOGY (2004)
Expansion of myeloid immune suppressor Gr+CD11b+cells in tumor-bearing host directly promotes tumor angiogenesis
L Yang et al.
CANCER CELL (2004)
Tolerance, DCs and tryptophan: much ado about IDO
U Grohmann et al.
TRENDS IN IMMUNOLOGY (2003)
CD4+CD25- T cells that express latency-associated peptide on the surface suppress CD4+CD45RBhigh-induced colitis by a TGF-β-dependent mechanism
T Oida et al.
JOURNAL OF IMMUNOLOGY (2003)
T cell apoptosis by tryptophan catabolism
I Fallarino et al.
CELL DEATH AND DIFFERENTIATION (2002)
Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade
Y Iwai et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase
G Frumento et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2002)
Inhibition of allogeneic T cell proliferation by indoleamine 2,3-dioxygenase-expressing dendritic cells:: Mediation of suppression by tryptophan metabolites
P Terness et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2002)
Reactivating the expression of methylation silenced genes in human cancer
AR Karpf et al.
ONCOGENE (2002)
分享论文
